Department of Neurosurgery, University of California at San Francisco (UCSF), 505 Parnassus Avenue Room M779, San Francisco, CA, 94143-0112, USA.
Wayne State University School of Medicine, 540 East Canfield, Detroit, MI, 48201, USA.
J Neurooncol. 2018 May;137(3):447-453. doi: 10.1007/s11060-018-2768-x. Epub 2018 Jan 18.
Glioblastoma is an aggressive brain malignancy with poor outcomes. Current standard of care involves surgery, radiotherapy and chemotherapy. Even with optimal treatment, 5-year survival rates are low. Many patients are unable to tolerate the considerable side effects that therapy involves and suffer from low quality of life. Anti-mitotic tumor treating fields have shown potential in treating glioblastoma with data suggesting that they prolong disease-free survival and overall survival. Novocure has marketed a device that generates these fields via externally placed electrodes. Incorporation of electric field therapy into GBM treatment has been somewhat slow, due to concerns about cost, practicality of its usage from a patient perspective, and hesitation of the medical and scientific community to embrace its unconventional mechanism. However, clinical trials have demonstrated this therapy has relatively minor side effects and high patient compliance. In this review, we explore the current state of this technology and discuss the benefits and limitations of tumor treating fields.
胶质母细胞瘤是一种侵袭性脑恶性肿瘤，预后较差。目前的标准治疗包括手术、放疗和化疗。即使采用最佳治疗，5 年生存率仍然较低。许多患者无法耐受治疗带来的严重副作用，生活质量较低。抗有丝分裂肿瘤治疗电场在治疗胶质母细胞瘤方面显示出了潜力，数据表明它们可以延长无疾病生存期和总生存期。Novocure 已经推出了一种通过外部放置电极产生这些电场的设备。由于担心成本、从患者角度考虑其使用的实用性以及医疗和科学界对其非传统机制的犹豫，电场疗法在 GBM 治疗中的应用进展缓慢。然而，临床试验已经证明这种疗法的副作用相对较小，患者的依从性较高。在这篇综述中，我们探讨了这项技术的现状，并讨论了肿瘤治疗电场的优缺点。
